→ Vor Bio made a Lazarus-like comeback in late June, nabbing the rights to RemeGen’s autoimmune drug telitacicept after closing the book on its clinical work in blood cancer ...
↧
Vor Bio hires former Sarepta exec to lead commercial strategy; Mallinckrodt poaches CFO from Incyte
↧